news

US-China trade war leaves gap for Indian pharma to grow

16
SHARES

A data analyst has reported that the current US-China trade war will give India chance to increase their pharmaceutical presence.

A market research company has stated the current US-China trade war has created a gap in the pharmaceutical market and suggest that India will be the ones to fill this space and expand their influence.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

GlobalData, a data analytics company, estimates that the Indian pharmaceutical market will fill the gap. They predict that India’s pharmaceutical industry will rise from nearly US$30.8 billion in 2018 to more than US$38.3 billion in 2022.

“This can be seen as a grace period where both China and the US could be looking out for alternatives. The Indian pharma industry can leverage this opportunity to become the partner of choice through strengthening its position in the US market and re-thinking on a long-term strategy for the China market,” says Prashant Khadayate, Pharma Analyst at GlobalData.

The Pharmaceuticals Export Promotion Council of India reports that the US accounts for more than 30 percent of total Indian pharma costs or US$5.82 billion worth of value from 2018-19.

The Council claims that 80 percent of the bulk drug imports in the US come from Chinese and Indian suppliers. India can use the new space in the market to increase their percentage. As the US has been the second largest supplier of drugs to China, making up 15 percent of its drug imports, India’s 0.1 percent is likely to grow as a result.

“China is dependent on the US for the drug formulations import. The Indian pharma industry can take advantage of this situation as it has proven abilities in both drug formulations and the bulk drugs category,” Khadayate continued. 

Share via
Share via